Stoneridge Investment Partners LLC Has $944,000 Stock Holdings in Baxter International Inc. $BAX

Key Points

• Stoneridge Investment Partners LLC reduced its holdings in Baxter International by 65.5%, now owning 27,583 shares worth approximately $944,000 after selling 52,258 shares in the 1st quarter.
• Several large investors increased their stakes in Baxter International, with SG Americas Securities LLC growing its holdings by 352.6% and Raiffeisen Bank International AG by 24.9%.
• Baxter International's stock received multiple target price reductions from analysts, with Barclays lowering it from $41 to $36 and UBS Group from $35 to $24, indicating a consensus rating of "Hold."

Stoneridge Investment Partners LLC trimmed its position in shares of Baxter International Inc. (NYSE:BAX - Free Report) by 65.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,583 shares of the medical instruments supplier's stock after selling 52,258 shares during the period. Stoneridge Investment Partners LLC's holdings in Baxter International were worth $944,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. BI Asset Management Fondsmaeglerselskab A S raised its stake in Baxter International by 41.7% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 20,063 shares of the medical instruments supplier's stock valued at $687,000 after buying an additional 5,907 shares during the last quarter. Horizon Investments LLC lifted its position in Baxter International by 5.0% during the first quarter. Horizon Investments LLC now owns 7,438 shares of the medical instruments supplier's stock worth $255,000 after buying an additional 351 shares in the last quarter. Zions Bancorporation National Association UT acquired a new stake in shares of Baxter International in the first quarter valued at $27,000. Nicholas Hoffman & Company LLC. grew its stake in Baxter International by 2.0% during the 1st quarter. Nicholas Hoffman & Company LLC. now owns 31,739 shares of the medical instruments supplier's stock worth $1,086,000 after purchasing an additional 636 shares in the last quarter. Finally, Raiffeisen Bank International AG grew its stake in Baxter International by 24.9% during the 1st quarter. Raiffeisen Bank International AG now owns 95,668 shares of the medical instruments supplier's stock worth $3,229,000 after purchasing an additional 19,081 shares in the last quarter. Institutional investors own 90.19% of the company's stock.

Baxter International Price Performance

Shares of NYSE:BAX traded up $0.6450 on Friday, reaching $24.4950. 6,487,397 shares of the company traded hands, compared to its average volume of 10,607,639. Baxter International Inc. has a fifty-two week low of $21.33 and a fifty-two week high of $40.49. The company's 50 day moving average is $27.46 and its 200-day moving average is $30.17. The stock has a market capitalization of $12.58 billion, a PE ratio of -81.65, a P/E/G ratio of 0.78 and a beta of 0.59. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.30 and a quick ratio of 1.49.

Baxter International (NYSE:BAX - Get Free Report) last released its earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.60 by ($0.01). Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The business had revenue of $2.81 billion during the quarter, compared to analysts' expectations of $2.82 billion. During the same quarter in the previous year, the company earned $0.68 EPS. Baxter International's revenue for the quarter was up 4.3% on a year-over-year basis. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. As a group, analysts anticipate that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 1st. Shareholders of record on Friday, August 29th will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Friday, August 29th. Baxter International's payout ratio is presently -226.67%.

Wall Street Analysts Forecast Growth

BAX has been the subject of a number of research analyst reports. Barclays decreased their target price on Baxter International from $41.00 to $36.00 and set an "overweight" rating for the company in a research report on Monday, August 4th. Citigroup cut their target price on Baxter International from $34.00 to $32.00 and set a "neutral" rating for the company in a research note on Wednesday, July 9th. Evercore ISI dropped their price objective on Baxter International from $44.00 to $42.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Stifel Nicolaus reaffirmed a "hold" rating and issued a $25.00 price objective (down from $36.00) on shares of Baxter International in a research note on Monday, August 4th. Finally, Wall Street Zen cut Baxter International from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Three equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Baxter International presently has a consensus rating of "Hold" and an average price target of $30.11.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.